BioCentury
ARTICLE | Company News

Servier declines rights to GeNeuro's GNbAC1

September 21, 2018 4:34 PM UTC

Servier (Neuilly-sur-Seine, France) declined to exercise an option to license rights outside the U.S. and Japan from GeNeuro S.A. (Euronext:GNRO) to develop and commercialize GNbAC1 to treat multiple sclerosis. The companies said Servier's decision was based on international development priorities. Servier will remain a GeNeuro shareholder.

In 2016, Servier gained the option to acquire the rights following the completion of the Phase IIb CHANGE-MS trial in relapsing-remitting MS (RRMS). In March, GeNeuro reported data from the trial showing the candidate given for 12 months reduced cortical atrophy and thalamic atrophy volume loss compared with a control group who received placebo for six months before switching to GNbAC1 for six months (see “GeNeuro Reports 12-Month Phase IIb Data for RRMS Candidate”)...